<DOC>
	<DOCNO>NCT02750930</DOCNO>
	<brief_summary>Albiglutide develop treatment type 2 diabetes mellitus ( T2DM ) adjunct diet exercise , monotherapy , combination exist therapy approve United States ( US ) Food Drug Administration ( FDA ) , European Medicines Agency ( EMA ) regulatory agency . This 26 week , open-label , single group , multicenter , extension study Study 200952 . This extension study provide extend safety , tolerability immunogenicity data albiglutide liquid drug product . This extension study comprise 2 study period : treatment ( 26 week ) post-treatment follow-up ( 8 week ) . A maximum 300 subject eligible take part extension study .</brief_summary>
	<brief_title>Extension Study 200952 Evaluate Long-term Safety , Tolerability Pharmacodynamics Albiglutide Liquid Drug Product Type 2 Diabetes Mellitus Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Subjects complete 26 week Treatment Phase Study 200952 Male female Able willing provide inform consent . Subject meet one withdrawal stop criterion Visit 1 ( Week 26 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Extension</keyword>
	<keyword>Long-term Safety</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Albiglutide</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>